| abstract |
It relates to a composition for treating lupus disease comprising Crif1 as an active ingredient, wherein the deficiency of Crif1 in the B cells of the present invention results in the development of lupus disease, and the deficiency of Crif1 in the B cells is IgG, IgG2c and IgG3 and each antibody It was confirmed to increase the formation, increase the expression of genes associated with inflammation, and increase the number of dysfunctional mitochondria. In addition, it was confirmed that the deficiency of Crif1 in B cells increased the activity of inflammation-related B cells and follicular helper T cells, and increased the amount of inflammation-related cytokines IL-6 and IL-17. It was confirmed that the disease was improved and the amount of anti-dsDNA IgG antibody decreased. |